Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We performed basic and clinical studies on the effects of a new oral quinolone derivative, levofloxacin (
LVFX
, Code No. DR 3355) which is an optical l-isomer of ofloxacin, in acute epididymitis.
LVFX
was administered in a dose of 200 mg to
prostatic cancer
patients 2 hours before operation. The mean concentration of
LVFX
in the tissues of testis and epididymis were 4.73 micrograms/g and 313-3.6 micrograms/g, respectively. Tissue/Serum ratios were 1.63 and 1.16-1.32, respectively.
LVFX
was administered in a dose of 100 mg three times daily for 13 days to healthy male volunteers. Semen and blood samples were taken 2 hrs after 7th and last day of administration. The concentration of
LVFX
in semen were 1.19 micrograms/ml (7th day) and 1.32 micrograms/ml (13th day). Semen/serum ratios were 1.12 and 1.26, respectively. No affection of
LVFX
on the sperm was observed. Antimicrobial activity of
LVFX
to C. trachomatis showed good MICs of 0.25-1.0 micrograms/ml.
LVFX
was administered in a dose of 100 mg two or three times daily for 14 days to 23 patients with acute epididymitis. The overall efficacy rate based on a criteria for acute epididymitis showed 100% (excellent: 16, good: 4, 20/20). A better efficacy rate was obtained on the 14th day than 7th day. No subjective or objective adverse reactions were observed.
...
PMID:[Acute nongonococcal epididymitis--pharmacological and therapeutic aspects of levofloxacin]. 160 77
